{"id":50723,"date":"2022-11-10T18:02:21","date_gmt":"2022-11-10T17:02:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/astrazeneca-evusheld-named-on-times-list-of-the-best-inventions-of-2022\/"},"modified":"2022-11-10T18:02:21","modified_gmt":"2022-11-10T17:02:21","slug":"astrazeneca-evusheld-named-on-times-list-of-the-best-inventions-of-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/astrazeneca-evusheld-named-on-times-list-of-the-best-inventions-of-2022\/","title":{"rendered":"AstraZeneca EVUSHELD Named on TIME\u2019s List of the Best Inventions of 2022"},"content":{"rendered":"
\n

WILMINGTON, Del.–(BUSINESS WIRE)–Today, TIME named AstraZeneca\u2019s EVUSHELD<\/a> (tixagevimab co-packaged with cilgavimab) on their 2022 list of Best Inventions. Their selection of EVUSHELD reflects its impact as the first and only long-acting monoclonal antibody to receive emergency use authorization in the US for the prevention of COVID-19 in immunocompromised people.\n<\/p>\n

<\/a><\/p>\n

\n“Immunocompromised individuals have lived a very different pandemic experience than most of us. EVUSHELD is an important scientific innovation, but it has also been a beacon of hope for those who have felt left behind in our return to normalcy. The inclusion of EVUSHELD in TIME\u2019s Best Inventions list is a testament to our commitment to advance the science of immune therapies to support this vulnerable population,” said Joris Silon, US Country President, BioPharmaceutical Business Unit, AstraZeneca.\n<\/p>\n

\nEVUSHELD is authorized for use for pre-exposure prophylaxis (prevention) of COVID-19 in the US (emergency use), EU, Japan and many other countries for people whose immune systems may be compromised by chemotherapy or other immunosuppressive drugs, or because they have hematologic malignancies, advanced or untreated HIV, a primary immune deficiency, or they have had a solid organ or bone marrow transplant.1,2<\/sup>\n<\/p>\n

\nTo compile the list, TIME solicited nominations from TIME\u2019s editors and correspondents around the world, paying special attention to growing fields. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition and impact.\n<\/p>\n

\nOf the new list, TIME\u2019s editors write: \u201cThe result is a list of 200 groundbreaking inventions (and 50 special mention inventions) \u2013 including life-mapping artificial intelligence, diamonds made from excess carbon in the air and the most powerful telescope ever \u2013 that are changing how we live, work, play and think about what\u2019s possible.\u201d\n<\/p>\n

\nSee the full list of TIME winners here: time.com\/best-inventions-2022<\/a>.\n<\/p>\n

\nIMPORTANT SAFETY INFORMATION<\/b>\n<\/p>\n

\nCONTRAINDICATIONS<\/span><\/span><\/b>\n<\/p>\n

\nEVUSHELD is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to EVUSHELD.\n<\/p>\n

\nWARNINGS AND PRECAUTIONS<\/span><\/span><\/b>\n<\/p>\n

\nHypersensitivity Including Anaphylaxis<\/b>\n<\/p>\n

\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with EVUSHELD. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and\/or supportive therapy. Clinically monitor individuals after injections and observe for at least 1 hour.\n<\/p>\n

\nRisk of Cross-Hypersensitivity with COVID-19 Vaccines<\/b>\n<\/p>\n

\nRisk of cross-hypersensitivity with COVID-19 vaccines exist as EVUSHELD contains polysorbate 80, which is in some COVID-19 vaccines and is structurally similar to polyethylene glycol (PEG), an ingredient in other COVID-19 vaccines.\n<\/p>\n

\nRisk for COVID-19 Due to SARS-CoV-2 Viral Variants Not Neutralized by EVUSHELD<\/b>\n<\/p>\n

\nCertain SARS-CoV-2 viral variants may not be neutralized by EVUSHELD. Inform individuals of the increased risk, compared to other variants, for COVID-19 due to SARS-CoV-2 viral variants not neutralized by EVUSHELD. If signs and symptoms of COVID-19 occur, advise individuals to test for COVID-19 and seek medical attention, including starting treatment for COVID-19 as appropriate.\n<\/p>\n

\nClinically Significant Bleeding Disorders<\/b>\n<\/p>\n

\nAs with any other intramuscular injection, EVUSHELD should be given with caution to individuals with thrombocytopenia or any coagulation disorder.\n<\/p>\n

\nCardiovascular Events<\/b>\n<\/p>\n

\nA higher proportion of subjects who received EVUSHELD versus placebo reported myocardial infarction and cardiac failure serious adverse events. All of the subjects with events had cardiac risk factors and\/or a prior history of cardiovascular disease at baseline. A causal relationship between EVUSHELD and these events has not been established.\n<\/p>\n

\nADVERSE REACTIONS<\/span><\/span><\/b>\n<\/p>\n

\nThe most common adverse events are headache, fatigue and cough.\n<\/p>\n

\nUSE IN SPECIFIC POPULATIONS<\/span><\/span><\/b>\n<\/p>\n

\nPregnancy<\/b>\n<\/p>\n

\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. EVUSHELD should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.\n<\/p>\n

\nLactation<\/b>\n<\/p>\n

\nThere are no available data on the presence of tixagevimab or cilgavimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. Maternal IgG is known to be present in human milk.\n<\/p>\n

\nPediatric Use<\/b>\n<\/p>\n

\nEVUSHELD is not authorized for use in pediatric individuals under 12 years of age or weighing less than 40 kg. The safety and effectiveness of EVUSHELD have not been established in pediatric individuals.\n<\/p>\n

\nAUTHORIZED USE FOR EVUSHELD<\/span><\/span><\/b>\n<\/p>\n

\nEVUSHELD is authorized for use under an EUA for the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):\n<\/p>\n